drugset / Trial / NCT03812770

Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC

NCT03812770

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with advanced hepatocellular carcinoma (HCC)

Timeline

Start
2018-08-04
Primary completion
2019-09-01
Completion
2019-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Leucovorin Small molecule Other
Comparator fluorouracil Small molecule Other
Background Oxaliplatin Small molecule Other
Background Sorafenib Small molecule 400 mg Oral